Molecular and immunohistochemical evaluation of BAP-1 antibody in bladder cancer and comparison with luminal-basal subtyping

Gürbüz, Begüm Çalım; Topal, Cumhur Selçuk; Sobay, Resul; Alkurt, Gizem; Zemheri, Ebru

doi:10.1016/j.prp.2020.153308

Cited by 7 publications

(6 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…GATA3 is an established marker of luminal papillary bladder tumours which are the least aggressive tumours and still retain some of the features of the urothelial differentiation (98). Similar to the results of this meta-analysis, four studies reported significant association between GATA3 expression and low grade (51,59,71,86) and low stage (51,59,71,86) tumours. GATA3 expression showed a significant association with tumour histology, with higher expression in UC as opposed to VH and UCDD, both in individual studies (57,60,70,77,79,84,86,90) and in our meta-analysis.…”

Section: Diagnostic Valuesupporting

confidence: 80%

Association Between Estrogen Receptors and GATA3 in Bladder Cancer: A Systematic Review and Meta-Analysis of Their Clinicopathological Significance

et al. 2021

View full text Add to dashboard Cite

BackgroundEstrogen receptors alpha (ERα) and beta (ERβ) and the cooperating protein GATA-binding factor 3 (GATA3) have been implicated in bladder carcinogenesis and tumour progression. GATA3 and ER have been functionally linked in the establishment of luminal fate in breast tissue, but to date their relationship in bladder cancer has not been established. This information will be useful to advance diagnostic and prognostic markers.AimTo determine the relationship between the expression of ERα, ERβ and GATA3 in bladder cancer, disclose their prognostic and diagnostic value and their association with clinicopathological characteristics.MethodsA comprehensive literature search in PubMed database was performed for all immunohistochemical studies of ERα, ERβ and/or GATA3 in bladder cancer patients. We selected eligible studies in accordance with the PRISMA guidelines and evaluated methodological quality and risk of bias based on quality criteria from the reporting recommendations for tumour MARKer (REMARK) prognostic studies. Risk of bias assessment was performed using Review Manager 5. R software was used for all statistical analysis, the packages used were meta and dmetar for the standard meta-analysis, and netmeta for the network meta-analysis.ResultsThirteen studies were eligible for ERα, 5 for ERβ and 58 for GATA3 meta-analysis. Low grade tumours showed significantly lower ERα expression. GATA3 was widely expressed in bladder tumours, especially urothelial carcinomas, with higher expression of GATA3 in low grade and low stage tumours. Data was insufficient to determine the prognostic value of either ERα or ERβ, but GATA3-positivity was associated with higher recurrence free survival. A negative correlation between ERα or ERβ positivity and GATA3 expression was disclosed. Additionally, several sources of heterogeneity were identified, which can be used to improve future studies.ConclusionThe clinicopathological value of ERα and ERβ was inconclusive due to low availability of studies using validated antibodies. Still, this meta-analysis supports GATA3 as good prognostic marker. On the contrary, ERα-positivity was associated to higher grade tumours; while ERα and ERβ were inversely correlated with GATA3 expression. Considering that it has previously been shown that bladder cancer cell lines have functional ERs, this suggests that ERα could be activated in less differentiated cells and independently of GATA3. Therefore, a comprehensive analysis of ERα and ERβ expression in BlaCa supported by complete patient clinical history is required for the identification of BlaCa subtypes and subgroups of patients expressing ERα, to investigate if they could benefit from treatment with hormonal therapy.Systematic Review RegistrationProspero, CRD42021226836.

show abstract

Section: Diagnostic Valuesupporting

confidence: 80%

Association Between Estrogen Receptors and GATA3 in Bladder Cancer: A Systematic Review and Meta-Analysis of Their Clinicopathological Significance

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Then, PBS was washed for 3 times and the corresponding species second antibody (catalog number: SV0002, BOSTER, Wuhan, China) was added. After incubating at room temperature for 50 min, the chromogenic agent, hematoxylin restaining, blue return, dehydration, transparent, and neutral resin seal were used [ 32 ].…”

Section: Methodsmentioning

confidence: 99%

Upregulation of Yin-Yang-1 Associates with Proliferation and Glutamine Metabolism in Esophageal Carcinoma

Luo

Chen

Bai

et al. 2022

International Journal of Genomics

View full text Add to dashboard Cite

Objective. To investigate the expression of Yin-Yang-1 (YY1) in esophageal carcinoma (ESCA) and its effect on glutamine metabolism in ESCA. Methods. The expression and roles of YY1 in ESCA were investigated using a series of bioinformatics databases and tools. The expression of YY1 between ESCA tissues with the corresponding adjacent tissues was validated using real-time PCR, western blot, and immunohistochemical staining method. Furthermore, the effects of YY1 on ESCC cell proliferation and migration were examined. The correlation between the YY1 and glutamine metabolism was evaluated by western blot. Results. YY1 gene was highly conserved in evolution and upregulated in ESCA tissues and ESCC cell lines (ECA109 and TE-1). In addition, YY1 may affect the level of immune cell infiltration and promote tumor cell immune escape. Functional enrichment analysis found that YY1 involved in many biological processes, such as cell division and glutathione and glutamine metabolism. After siRNA knockdown of YY1 in ECA109 and TE-1, the proliferation and the migration of ECA109 and TE-1 were suppressed. The glutamine consumption and glutamate production were significantly decreased. The protein expression of alanine-, serine-, cysteine-preferring transporter 2 (ASCT2), glutaminase (GLS), and glutamate dehydrogenase (GLUD1) was significantly downregulated. Conclusion. YY1 is highly expressed in ESCA and may promote glutamine metabolism of ESCC cells, indicating it may be as a diagnostic biomarker for ESCA.

show abstract

“…The ubiquitin signal from the mouse liver tissue sample was detected using ThUBD, an anti-ubiquitin antibody and ThUBD-HRP separately in parallel. 24 Briefly, the pre-treated tissue sections were incubated with ThUBD-HRP, an ubiquitin antibody or ThUBD diluted with 5% BSA. ThUBD and ThUBD-HRP were diluted at 1 : 1000, and the ubiquitin antibody was diluted at 1 : 500.…”

Section: Immunohistochemical (Ihc) Analysismentioning

confidence: 99%

Chemically labeled ThUBD permits rapid and super-sensitive imaging of polyubiquitination signals

Xiao

Huang

Gao

et al. 2022

Analyst

View full text Add to dashboard Cite

show abstract

Molecular and immunohistochemical evaluation of BAP-1 antibody in bladder cancer and comparison with luminal-basal subtyping

Cited by 7 publications

References 32 publications

Association Between Estrogen Receptors and GATA3 in Bladder Cancer: A Systematic Review and Meta-Analysis of Their Clinicopathological Significance

Association Between Estrogen Receptors and GATA3 in Bladder Cancer: A Systematic Review and Meta-Analysis of Their Clinicopathological Significance

Upregulation of Yin-Yang-1 Associates with Proliferation and Glutamine Metabolism in Esophageal Carcinoma

Chemically labeled ThUBD permits rapid and super-sensitive imaging of polyubiquitination signals

Contact Info

Product

Resources

About